Presentation by Julia Reynolds, Associate Director for Transformation - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Professsor John Gladman - Caring for older people and stroke survivorsCLAHRC-NDL
Caring for older people and stroke survivors theme presentation by Professor John Gladman, delivered at the NIHR CLAHRC East Midlands launch event on 14 February 2014, Loughborough.
Five priorities for care of the dying personMarie Curie
Dr Bill Noble, Medical Director of Marie Curie Cancer Care, speaks at the end of life sesion with Dr Adam Firth (RCGP Clinical Support Fellow for End of Life Care).
This session was chaired by Dr Peter Nightingale, Marie Curie and RCGP End of life lead at the RCGP Annual Conference, ACC Liverpool, 2-4 October, 2014.
For more information visit: mariecurie.org.uk/rcgp
Presentation by Dr Martin Myers MBE, PhD, FRCPath, Consultant Clinical Biochemist, Lancashire Teaching Hospitals NHS Foundation Trust at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Apresentação realizada no I Seminário Internacional de Atenção às Condições Crônicas, pela diretora do Programa da Gestão de Doenças Crônica dos Serviços Sanitários De Alberta/Canadá, Sandra Delon.
Belo Horizonte, 11 de novembro de 2014
Value of secondary prevention in cardiac rehabilitationShagufaAmber
. Treatment of acute event: An initial step in the CV care continuum occurs when treatments are given to address the acute CVD event at hand. For an acute coronary syndrome, prompt provision of antiplatelet therapy, thrombolytic therapy, percutaneous coronary intervention, or some combination of these is critically important to help patients survive the acute event and to do so with minimal damage to the heart.2. Initiation of Secondary Prevention (SP) therapies: A second step in the care continuum occurs shortly after the acute event has resolved and a longer-term treatment plan is initiated. This long-term plan generally includes lifesaving lifestyle and medical therapies and is ideally started before discharge. In fact, evidence shows that when SP treatments are started in the hospital, patients are more likely to adhere to those treatments in the long term, and are more likely to remain free from recurrent CV events than when those treatments were not started before discharge.
Better outcomes, better value: integrating physical and mental health into clinical practice and commissioning
Tuesday 24 June 2014: 15 Hatfields, Chadwick Court, London
This presentation aids a Health and Wellbeing Board session on developing prevention across the health and social care system, in answer to financial challenges and the NHS FIve Year Forward View
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
More Related Content
Similar to Introduction to Supporting recovery in Primary Care using Proactive Frameworks for LTCs
Professsor John Gladman - Caring for older people and stroke survivorsCLAHRC-NDL
Caring for older people and stroke survivors theme presentation by Professor John Gladman, delivered at the NIHR CLAHRC East Midlands launch event on 14 February 2014, Loughborough.
Five priorities for care of the dying personMarie Curie
Dr Bill Noble, Medical Director of Marie Curie Cancer Care, speaks at the end of life sesion with Dr Adam Firth (RCGP Clinical Support Fellow for End of Life Care).
This session was chaired by Dr Peter Nightingale, Marie Curie and RCGP End of life lead at the RCGP Annual Conference, ACC Liverpool, 2-4 October, 2014.
For more information visit: mariecurie.org.uk/rcgp
Presentation by Dr Martin Myers MBE, PhD, FRCPath, Consultant Clinical Biochemist, Lancashire Teaching Hospitals NHS Foundation Trust at ECO 19: Care closer to home on Tuesday 9 July at Deepdale Stadium.
Apresentação realizada no I Seminário Internacional de Atenção às Condições Crônicas, pela diretora do Programa da Gestão de Doenças Crônica dos Serviços Sanitários De Alberta/Canadá, Sandra Delon.
Belo Horizonte, 11 de novembro de 2014
Value of secondary prevention in cardiac rehabilitationShagufaAmber
. Treatment of acute event: An initial step in the CV care continuum occurs when treatments are given to address the acute CVD event at hand. For an acute coronary syndrome, prompt provision of antiplatelet therapy, thrombolytic therapy, percutaneous coronary intervention, or some combination of these is critically important to help patients survive the acute event and to do so with minimal damage to the heart.2. Initiation of Secondary Prevention (SP) therapies: A second step in the care continuum occurs shortly after the acute event has resolved and a longer-term treatment plan is initiated. This long-term plan generally includes lifesaving lifestyle and medical therapies and is ideally started before discharge. In fact, evidence shows that when SP treatments are started in the hospital, patients are more likely to adhere to those treatments in the long term, and are more likely to remain free from recurrent CV events than when those treatments were not started before discharge.
Better outcomes, better value: integrating physical and mental health into clinical practice and commissioning
Tuesday 24 June 2014: 15 Hatfields, Chadwick Court, London
This presentation aids a Health and Wellbeing Board session on developing prevention across the health and social care system, in answer to financial challenges and the NHS FIve Year Forward View
Similar to Introduction to Supporting recovery in Primary Care using Proactive Frameworks for LTCs (20)
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
Supporting the optimal detection and management of BP in Primary CareInnovation Agency
Presentation by Jane Briers, Programme Manager - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Dr Lauren Moorcroft, GP Partner - Brookvale Practice at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Paul Brain, Project Manager at the Excel in Health series - Introduction to data webinar on Monday 6 June 2022.
In this session we discussed how SMEs can use data to grow their business and access new opportunities in the market.
Presentations by Mike Kenny, Acting Co-Director of Enterprise and Growth, Innovation Agency and Dr Neil Paul, a GP and Board Member with Cheshire East ICP at the Excel in Health: Understanding the NHS Landscape webinar on Wednesday 11 May 2022.
LCR and Cheshire and Merseyside Health MATTERS networking eventInnovation Agency
Master slide deck from the LCR and Cheshire and Merseyside Health MATTERS networking event on Wednesday 24 November 2021 at Sci-Tech Daresbury Laboratory.
Master slide deck from the Excel in Health webinar series: The NHS landscape presentation.
This webinar identifies the structure of the NHS and its national priorities.
The session will cover the following topics:
Understand the structure of the NHS
Understand the national priorities of the NHS
Recognise the barriers to sale
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Introduction to Supporting recovery in Primary Care using Proactive Frameworks for LTCs
1. Supporting Recovery in Primary Care
UCLP Proactive Care Frameworks for
Long Term Conditions
Dr Julia Reynolds PhD
Associate Director for Transformation
Innovation Agency
2. Welcome!
HOUSEKEEPING
Delegates are muted for this session.
This session will be recorded and shared with delegates post event.
QUESTIONS
If you have any questions about the presentations you have seen, please enter them into the
Q&A box.
AGENDA
3 presentations – Case Studies
• Blood Pressure (PCN)
• Respiratory (GP Federation)
• Multimorbidity (GP practice)
3. COVID-19: Impact on Proactive Care in
Long Term Conditions
Urgent challenge
• Pandemic resulted in overnight transformation in primary care: universal shift to remote
care and reduced face to face access
• Disruption of routine, proactive care in long term conditions such as CVD, hypertension,
diabetes, COPD, asthma
• Risk of deterioration/exacerbation in long term conditions driving further waves of demand
for urgent and acute care and worse outcomes for patients
Opportunity
• Restore and transform proactive care for people with long term conditions
• Support a step change in Personalised Care
• Mobilise wider primary care workforce to support remote care and self management
• Optimise clinical care and reduce variation
4. Our challenge
• Large number of excess
deaths due to COVID
• High levels of health
inequalities
• Industrial legacy – poor
health
• High level of deprivation
• High levels of variation
• Variable staff levels and
staffing profiles
8. The frameworks
Systematic
support for
primary care to
restore and
improve
proactive care
• Comprehensive search tools to risk stratify
patients – built for EMIS and SystmOne
• Stratifying the population - Pathways that
prioritise patients for follow up, support remote
delivery of care, and identify what elements of
LTC care can be delivered by staff such as
Health Care Assistants and link workers.
• Scripts and protocols to guide Health Care
Assistants and others in their consultations.
• Using the wider workforce - Training for
staff to deliver education, self-management
support and brief interventions. Training
includes health coaching and motivational
interviewing.
• Using remote monitoring - Digital and
other resources that support remote
management and self-management.
9. Primary Care
Incentive
Opportunities
– CVD
Prevention
22/23
• CVD 01 & CVD 02 – Hypertension patients on the QOF
Hypertension Register
• CVD 03 – Lipids Patients with a QRISK2/3 who are treated
with statins
• CVD 04 – Lipids Patients 29 and under with with total
cholesterol >7.5 referred for assessment for familial
hypercholesterolemia and those over 29 referred if total
cholesterol is more than 9
• CVD 05 – Atrial Fibrillation CHA2DSVASc >2 (female) & >1
(not female) prescribed anti-coagulation
• CVD 06 – Atrial Fibrillation Patients prescribed Edoxaban
• PC01 – Personlised Care Referrals to social prescriber
• SMR02C – Structured medicine reviews
• RESP 01 – Asthma Patients on more than 3 inhalers (ICS) in
last 12 months
• RESP 02 Asthma patients who received more that 6 SABA
prescriptions
• ES01 – Environmental sustainability inhaler prescriptions
• ES02 – Environmental sustainability – inhaler carbon
emissions
10. Personalised care
conversation: Starting
with what matters to
John, knowledge, skills
and confidence,
holistic view of ‘whole
lives’ and outcomes
they want to achieve,
and SDM conversation
re range of options
available?
Measurement of
digital and health
literacy, baselining
level of self-
management?
Digital skills, small
PHBs?
Signposting to digital
tools? PHB to access
digital equipment?
Development of a
PCSP or wellbeing
plan?
Preparing people for
SDM conversation
with clinician ‘
Prepared Patient?
Workforce training and culture shift
Shared Decision
Making
Conversation?
Review of PCSP?
Shared Decision
Making Conversation?
Review / development
of PCSP?
Isolated, not connected to community?
So what? What is the impact/outcomes?